⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Official Title: A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion

Study ID: NCT01752920

Conditions

Solid Tumor

Study Description

Brief Summary: This was an open-label, Phase 1/2, dose escalation and signal finding study of derazantinib administered to patients with advanced solid tumors (Part 1; Dose Escalation/Food-effect Cohorts) or with advanced solid tumors with FGFR genetic aberrations, including iCCA with FGFR2 gene fusion (Part 2; Expanded Cohort, signal finding).

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Scottsdale Healthcare Research Institute, Scottsdale, Arizona, United States

Emory University, Winship Cancer Institute, Atlanta, Georgia, United States

Karmanos Cancer Institute, Detroit, Detroit, Michigan, United States

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States

Montefiore-Einstein Center for Cancer Care, Bronx, New York, United States

University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States

University of Washington, Seattle, Washington, United States

Istituto Clinico Humanitas, Milan, , Italy

Istituto Nazionale Tumori (National Cancer Institute), Milan, , Italy

Instituto Oncologico Veneto, IRCCS, Padova, , Italy

Azienda Ospedaliero-Universitaria Pisana - U.O. Oncologia Medica 2 Univ., Pisa, , Italy

Contact Details

Name: Marc Engelhardt, MD

Affiliation: Basilea Pharmaceutica

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: